1. Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
- Author
-
Fabio Salvatore Macaluso, Gaetano Inserra, Marco Ventimiglia, Maria Cappello, Mario Cottone, Antonio Carroccio, Angela Alibrandi, Antonino Carlo Privitera, Walter Fries, Filippo Mocciaro, N. Belluardo, A. Magnano, Sara Renna, S. Siringo, S. Garufi, Serena Porcari, C. Ferracane, Ambrogio Orlando, Alessandro Vitello, C. Bertolami, Oriana Fidanza, Roberto Di Mitri, Anna Viola, G. Magrì, and Porcari S, Viola A, Orlando A, Privitera AC, Ferracane C, Cappello M, Vitello A, Siringo S, Inserra G, Magnano A, Mocciaro F, Di Mitri R, Belluardo N, Fidanza O, Garufi S, Magrì G, Bertolami C, Carroccio A, Macaluso FS, Renna S, Ventimiglia M, Alibrandi A, Cottone M, Fries W
- Subjects
Adult ,Male ,medicine.medical_specialty ,Settore MED/09 - Medicina Interna ,Drug-Related Side Effects and Adverse Reactions ,Kaplan-Meier Estimate ,Anti-Tumour Necrosis Factor ,Disease ,Inflammatory bowel disease ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Treatment Failure ,030212 general & internal medicine ,Adverse effect ,Aged ,Retrospective Studies ,Aged, 80 and over ,Tumor Necrosis Factor-alpha ,business.industry ,Inflammatory Bowel Disease ,Adalimumab ,Age Factors ,Antibodies, Monoclonal ,Retrospective cohort study ,Middle Aged ,Inflammatory Bowel Diseases ,medicine.disease ,Ulcerative colitis ,Infliximab ,Sicilian Network for Inflammatory Bowel Diseases (SN-IBD) ,Withholding Treatment ,Concomitant ,Female ,Geriatrics and Gerontology ,business ,030217 neurology & neurosurgery ,Cohort study - Abstract
BACKGROUND AND OBJECTIVE: Older people with inflammatory bowel disease (IBD) appear to have a lower response to anti-tumour necrosis factor (TNF) therapy, with more frequent complications than younger patients. The objective of this study was to assess persistence on therapy and the safety of anti-TNF therapy in older patients (aged ≥ 60 years). METHODS: We retrospectively reviewed the database of the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD), extracting data regarding IBD patients aged ≥ 60 years and controls
- Published
- 2020